Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Motzer, R; Hutson, T; Cella, D; Reeves, J; Hawkins, Robert E; Guo, J; Nathan, P; Staehler, M; de Souza, P; Merchan, J; Boleti, E; Fife, K; Jin, J; Jones, R; Uemura, H; De Giorgi, U; Harmenberg, U; Wang, J; Sternberg, C; Deen, K; McCann, L; Hackshaw, M; Crescenzo, R; Pandite, L; Choueiri, T

Affiliation

Department of Medicine, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, USA.

Issue Date

2013-08-22

Metadata

Show full item record

Abstract

Pazopanib and sunitinib provided a progression-free survival benefit, as compared with placebo or interferon, in previous phase 3 studies involving patients with metastatic renal-cell carcinoma. This phase 3, randomized trial compared the efficacy and safety of pazopanib and sunitinib as first-line therapy.

Citation

Pazopanib versus sunitinib in metastatic renal-cell carcinoma. 2013, 369 (8):722-31 N Engl J Med

Journal

The New England Journal of Medicine

URI

http://hdl.handle.net/10541/304738

DOI

10.1056/NEJMoa1303989

PubMed ID

23964934

Type

Article

Language

ISSN

1533-4406

Collections

All Paterson Institute for Cancer Research